← Browse by Condition

Medical Condition

sarcoma

Total Trials

22

Recruiting Now

22

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for sarcoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — sarcoma Clinical Trials

How many clinical trials are currently recruiting for sarcoma?

ClinicalMetric currently tracks 22 actively recruiting clinical trials for sarcoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 22. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for sarcoma?

sarcoma research spans Phase 1 (8 trials), Phase 2 (7 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a sarcoma clinical trial?

Eligibility criteria for sarcoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

8

Phase 2

7

Top Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University 1 trial

Ruijin Hospital 1 trial

Shenzhen Geno-Immune Medical Institute 1 trial

Washington University School of Medicine 1 trial

Epkin 1 trial

Recruiting Clinical Trials

NCT07501026 Phase 2

Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC)

Second Affiliated Hospital, Sc...

NCT04072042 Phase 2

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Ruijin Hospital

NCT04433221 Phase 1, Phase 2

Combination Immunotherapy Targeting Sarcomas

Shenzhen Geno-Immune Medical I...

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Washington University School o...

NCT06789172 Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

United States, Austr...

NCT05492682 Phase 1

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

NCT06508307 Phase 1

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

GONGCHU Biotechnology Co., Ltd

NCT03465592 Phase 1, Phase 2

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Sidney Kimmel Comprehensive Ca...

Fluorescence-Guided Optimization of Sarcoma Margins

University of Aarhus

Tumor-Lymph Node Mapping

University of Rochester

GISAR German Interdisciplinary Sarcoma Registry

Institut für Klinische Krebsfo...

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

Rigshospitalet, Denmark

Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study

Roswell Park Cancer Institute

NCT06298916 Phase 1, Phase 2

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Lantheus Medical Imaging

Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

Technische Universität Dresden

Video Education With Result Dependent dIsclosure

Dana-Farber Cancer Institute

NCT04719156 Phase 2

Fluorescent Intra-operative Tumor Margin Examination

DESTINY-PANTUMOUR04

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Royal Marsden NHS Foundation T...

NCT06889766 Phase 1

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

Centre Hospitalier Universitai...

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

NCT06710756 Phase 1, Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Perspective Therapeutics

Related Conditions

ovarian cancer (5) head and neck cancer (4) esophageal cancer (4) colorectal cancer (4) pancreatic cancer (4) prostate cancer (3) breast cancer (3) melanoma (3) cervical cancer (3) gastric cancer (3) colon cancer (2) lung cancer (2)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology